Reversed reverse remodeling: can biomonitoring solve the clinical conundrum of the 3Rs?

Circ Heart Fail. 2014 May;7(3):388-90. doi: 10.1161/CIRCHEARTFAILURE.114.001357.

Authors

James L Januzzi Jr¹, Paul J Hauptman²

Affiliations

¹ From the Division of Cardiology, Massachusetts General Hospital, Boston (J.L.J.); and the Division of Cardiology, Department of Medicine, St Louis University School of Medicine, MO (P.J.H.). [email protected].
² From the Division of Cardiology, Massachusetts General Hospital, Boston (J.L.J.); and the Division of Cardiology, Department of Medicine, St Louis University School of Medicine, MO (P.J.H.).

PMID: 24847126
DOI: 10.1161/CIRCHEARTFAILURE.114.001357

No abstract available

Keywords: Editorials; drug therapy; heart failure.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Female
Heart Failure / drug therapy*
Heart Failure / physiopathology*
Humans
Male
Stroke Volume / physiology*
Ventricular Dysfunction, Left / drug therapy*
Ventricular Dysfunction, Left / physiopathology*

Substances

Adrenergic beta-Antagonists